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Abstract
Purpose of Review Discontinuation of tyrosine kinase inhibitors (TKIs) in chronic phase chronic myeloid leukemia (CP-CML)
patients has become a reality. Treatment-free remission (TFR) is the term that identifies success after discontinuation.
Recent Findings Several trials have demonstrated that with imatinib about 40% of patients discontinuing treatment in deep and
stable molecular response remain disease-free. Second-generation TKIs have improved the rate of deep molecular responses and
allowed to increase the percentage of patients attempting treatment discontinuation.
Summary We hereby review the current information based on the available published data and discuss the current suggestions on
how to move TFR into the clinical practice.
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Introduction
Imatinib has dramatically impacted on the management of
chronic myeloid leukemia (CML) allowing to obtain more
than 80% of complete cytogenetic responses (CCyR) and
long-term overall survival (OS) rates greater than 90%, con-
sidering only CML-related deaths [1••]. However, deep mo-
lecular responses, measured by reductions of BCR-ABL tran-
script levels below the threshold of major molecular response
(MMR, ratio BCR-ABL/ABL < 0.1% according to the
International Scale (IS)) are achieved only by a small propor-
tion of patients [2]. The frontline use of the second-generation
tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib in
newly diagnosed patients has increased the proportion of pa-
tients achieving very deep and stable molecular responses [3•,
4•]. New cut-offs of molecular residual disease have been
defined following the introduction of more potent and selec-
tive TKIs as frontline treatment: MR4, corresponding to a
BCR-ABL ratio < 0.01%, MR4.5, corresponding to a ratio
< 0.0032%, and MR5, corresponding to a 5-log reduction or
< 0.001% according to the IS [5••].
In 2006, John Goldman introduced in the clinical practice
the clinical definition of “operational cure” [6] following the
observation that some patients after an allogeneic stem cell
transplant or interferon therapy could discontinue treatment.
In these patients, molecular monitoring by RQ-PCR demon-
strated the persistence of residual disease, that however did
not require to restart treatment. This observation then translat-
ed into the era of TKIs: the term “treatment-free remission”
(TFR) indicates the possibility of remaining without treatment
after the achievement of a stable and deep long-lasting molec-
ular response [7].
Aim of this review is to report and analyze the results of the
different published discontinuation studies and to discuss the
recommendations on how to optimally define potential candi-
dates to TFR, the new endpoint in the management of CML
patients.
Imatinib Discontinuation Trials
The first pilot study was reported by the French group, which
tested the discontinuation of imatinib in 12 CML patients with
undetectable molecular disease lasting for more than 2 years.
Molecular relapse was defined as RQ-PCR positivity
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confirmed in two consecutive samples. All but two patients
had been pre-treated with interferon for a median of
33 months, whereas the median time of imatinib treatment
was 45 months. Molecular relapse occurred in six patients
(50%) within the first 5 months, but all were successfully
retreated. Owing to the few patients enrolled, the group did
not identify predictive prognostic factors for relapse, except
for a trend for a shorter time to RQ-PCR negativity in non-
relapsing patients [8].
The STIM1 study was a prospective trial in which 100 CP-
CML patients with undetectable molecular disease (defined as a
5-log reduction) for more than 2 years after imatinib treatment
were enrolled. Fifty-one percent of patients had been previously
exposed to interferon. Molecular relapse was defined as two
positive RQ-PCR controls 1 month apart with a significant rise
of 1-log in the BCR-ABL transcript. At the last reported follow-
up of 77 months, 61 of the 100 patients had relapsed; 58 of
them were early relapses occurring during the first 7 months of
discontinuation and 3 were late relapses, with no relapses ob-
served after the second year. The cumulative incidence of re-
lapse was estimated to be about 60%. During the discontinua-
tion period, five deaths occurred for CML non-related causes.
All relapsed patients were successfully retreated (48 patients
with imatinib and 10 patients with a second-generation TKI)
and all regained a molecular response: no patient developed
mutations of kinase domains or progressed to an advanced
phase of the disease. An initial sub-analysis performed to iden-
tify prognostic features predictive for stable complete molecular
response (CMR) after imatinib discontinuation showed that a
low Sokal risk and a long treatment duration prior to discontin-
uation were two independent factors associated with a low rate
of molecular relapse [9••].
The prospective TWISTER study was the second example
of discontinuation trial carried out by the Australian group: 40
CML patients with undetectable molecular disease (MR4.5)
lasting for more than 2 years after a minimum of 36 months
of imatinib treatment were enrolled. Molecular relapse was de-
fined as any single sample with loss of MMR (ratio > 0.1%) or
two consecutive positive samples of any value confirming the
loss of undetectable response. Again, as in the STIM1 study, 21
patients had been previously pre-treated with interferon. At
24 months, the estimated rate of TFR was 42.7%, with the
majority of relapses occurring in the first 6 months and seven
as late relapses that occurred between 6 and 27 months. A
different behavior was observed in relapsed patients: the medi-
an fold-rise of the transcript level in patients with earlier re-
lapses was 91.5 with a median BCR-ABL doubling time of
12.8 days, whereas the median fold-rise was 3.3 in patients with
late relapses with a median doubling time of 72.2 days. The
rechallenge with the same drug was successful in all patients.
The relapse risk was significantly associated with a shorter
duration of the previous IFN treatment, time to achieve unde-
tectable disease after switching from IFN to imatinib and a high
Sokal risk. Patient-specific PCR based on DNA was tested in
this trial: this tool demonstrated the persistence of the original
CML clone in all patients with stable molecular response, even
after several years from imatinib discontinuation [10].
The KIDS multicenter prospective Korean discontinuation
study enrolled a total of 48 patients on treatment with imatinib
for more than 3 years who had an undetectable molecular
response for at least 2 years. Twenty patients had previously
received an allogeneic transplant and were treated with ima-
tinib after relapse. Endpoints were the probability of a
sustained UMRD (undetectable response) and MMR at
12 months after discontinuation, and the identification of fac-
tors predictive of a sustained molecular response. Relapse was
considered as the loss of MMR. After a median follow-up of
26.6 months, 37 patients lost the MMR with a probability of
maintaining a MR3 at 24 months of 58.5%. All patients who
restarted imatinib after relapse obtained again a MR3 after a
median of 3.9 months. Long-term duration of imatinib treat-
ment and the occurrence of musculoskeletal pain, known as
“whitdrawal syndrome” were associated with a sustained
MR3 after discontinuation [11].
The French group reported an analysis on 80 patients who
were included in the so-called “According to STIM” experi-
ence: patients were enrolled if they had achieved a MR4.5 or
an undetectable disease for at least 2 years. The criterion to
define a molecular relapse was the loss of MMR; using this
endpoint, after a median follow-up of 36 months, 61% of pa-
tients remained treatment-free. Previous IFN therapy seemed to
prolong the treatment-free survival. A fluctuation of the molec-
ular levels above 0.1% IS without relapse and need to restart
treatment was demonstrated in 31% of patients [12•].
After the first STIM1 study, further studies have been re-
ported following treatment with imatinib. These include
STIM2 [13] which enrolled only patients treated with imatinib
first-line (without previous exposure to IFN) and the Japanese
study STIM213, which reported a TFR at 12months of 69.1%
in patients treated with imatinib for more than 3 years and in
stable MR4.5 for almost 2 years [14]. An Italian study (ISAV)
enrolled 112 patients treated with imatinib, even after previous
IFN exposure, who discontinued treatment when in MR4.5
and considering as relapse the loss of MR3. A molecular re-
lapse was experienced by 50.9% of patients, the majority oc-
curring during the first 9 months (70.9%). Two patients were
described as having a late relapse after 30.5 and 45.5 months.
Fifty-three patients experienced a fluctuation of molecular re-
sidual disease without losing MR3. No correlations were
found in this study between occurrence of relapse and median
time of treatment, median time of deep MR, previous IFN
exposure and Sokal risk. An inverse correlation between age
and risk of relapse was shown, with an increased risk in pa-
tients aged less than 45 years. Digital PCR was tested in this
trial and a significant predictive value with early relapses was
reported [15]. A retrospective Italian study showed the
23 Page 2 of 9 Curr Oncol Rep (2018) 20: 23
outcome of patients after discontinuation performed outside of
clinical trials because of toxicity, pregnancy or other reasons.
Two hundred and eight patients were collected in 23 different
institutions, median age was 59 years, with 13% of patients
having a high Sokal risk. Eighty-one percent of patients were
treated frontline (74% with imatinib) with a median duration
of CMR before discontinuation of 23 months. The TFR at
28 months was 59.3%. In multivariate analysis, predictive
factors associated to an increased risk of relapse were younger
age and depth of response at the time of discontinuation [16]
(Table 1).
The EURO-SKI Study
A large European study was conducted supported by the
EUTOS group. Patients were allowed to enter if on treatment
with all available TKIs for more than 3 years and in stable
MR4 for more than 1 year. After a confirmation of MR4 dur-
ing an initial screening phase, patients who discontinued were
monitored every month for the first 6 months, then every
6 weeks up to the end of the first year and thereafter every
3 months. Seven hundred and fifty patients were analyzed;
18% of them had a high Sokal risk at presentation. Themedian
age was 52 years, whereas the median duration of treatment
was 7.7 years and the median duration of MR4 before
treatment discontinuation was 4.7 years. Ninety-four percent
of patients were treated with imatinib, 2% with dasatinib, and
4% with nilotinib. The molecular relapse-free survival at
36 months was 50%, with 413 patients remaining in MR3 at
the last follow-up. Univariate analysis of prognostic factors
associated with a molecular relapse-free survival (RFS) at
6 months showed that age, gender, depth of molecular re-
sponse, or any initial stratification (Sokal, EUTOS or ELTS
score) were not predictive. Indeed, treatment duration with
imatinib and MR4 duration had similar odds ratio of 1:16,
which means that any additional year of imatinib treatment
increases the likelihood of remaining in MR3 at 6 months by
16%. A cut-off of imatinib treatment duration > 5.8 years and
of MR4 duration > 3.1 years before attempting discontinua-
tion were found. None of the patients who lost the MR3
progressed or died from the disease and 72 patients had an
increased ratio > 1%.More than 80% of patients who restarted
treatment after relapse regained a MR4. A saving of 27 mil-
lions of euro was estimated [17•]. A sub-analysis of the study
evaluated the molecular RFS according to the level of molec-
ular response at the time of discontinuation: no differences
were detected for patients in MR4 who never achieved a
MR4.5 (RFS 61%) compared to detectable MR4.5 (51%) or
undetectable MR4.5 (62%) [18]. A subsequent analysis re-
ported also the differences between detectable and undetect-
able MR4 without differences in molecular RFS [19].
Table 1 Overview of imatinib discontinuation trials
Study No. of
pts
Treatment Response required
at study entry
Relapse threshold Median
duration of
therapy at
study entry
TFR
outcome
STIM1 100 Imatinib
(1st line or after IFN)
>MR4.5 (undetectable
transcript for at least
2 years)
Loss of CMR or
increase of > 1 log
> 3 years 39% at
77 months
TWISTER 40 Imatinib
(1st line or after IFN)
MR4.5 (undetectable transcript
for at least 2 years)
Loss of confirmed
MR4.5 or MMR
> 3 years 42.7% at
24 months
A-STIM 80 Imatinib
(1st line or after IFN)
MR4.5 for at least 2 years Loss of MMR > 3 years 61% at
36 months
KIDS 90 Imatinib
(1st line or after IFN)
MR4.5 (undetectable
transcript for at least
2 years)
Loss of MMR > 3 years 58.5% at
24 months
ISAV 108 Imatinib
(1st line or after IFN)
MR4 or 4.5
(undetectable transcript for
at least 18 months)
Loss of MMR > 3 years 50.9% at
45 months
STIM2 124 Imatinib
(1st line)
>MR4.5 (undetectable
transcript for at least
2 years)
Positivity of RQ-PCR
confirmed indicating
increase of one log or loss of
MMR at one point.
> 3 years 61% at
1 year
STIM213 77 Imatinib
(1st line or after IFN)
MR4 for more than 24
months confirmed on
4 tests
Loss of MMR > 3 years 67.6% at
1 year
EUROSKI
750 Imatinib
(1st line or after IFN) and
dasatinib or nilotinib
MR4 for at least 1 year Loss of MMR > 3 years 50% at
36 months
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First Examples of Second-Generation TKI
Discontinuation Trials
STOP second-generation TKIs was the first example of dis-
continuation of dasatinib and nilotinib performed by the
French CML group. Patients enrolled were treated with
second-generation TKIs for more than 3 years as second line
after resistance and/or intolerance to imatinib, and who were
in undetectable response after more than 24 months. The pri-
mary endpoint was to establish survival without loss ofMMR,
which defined the criterion for molecular relapse and for re-
sumption of therapy. Sixty patients who discontinued treat-
ment were reported (30 treated with nilotinib and 30 with
dasatinib); only 13% of them had a high Sokal risk at presen-
tation, 67% were intolerant to imatinib. Only 10% were treat-
ed frontline. After a minimum follow-up for all patients of
12 months, the probability of remaining in stable MMR was
63.3%. No progressions to advanced phase of the disease were
recorded. Analysis of variables associated to stable MMR
showed that suboptimal response or treatment failure were
associated with a high probability of relapse, but the analysis
was impaired due to the small sample size. The majority of
patients relapsed before 12 months of discontinuation (21 pa-
tients) and only five after 12 months [20].
The Japanese group reported the results of the DADI trial
in which 63 patients were treated second line with dasatinib: to
be enrolled, patients were required to have a molecular re-
sponse < 0.0069% maintained for more than 1 year and the
relapse was defined as the loss of MR4. Again, the majority of
relapses occurred in the first 7 months from discontinuation
and the probability of TFR at 12months was 48%. All patients
regained response after rechallenge with the same drug or with
nilotinib (one patient). An increased probability of maintain-
ing a TFR was observed in patients intolerant to imatinib
(65%) rather than resistant (10%) [21] (Table 2).
Dose De-escalation as a Strategy for TFR
The UK group reported the feasibility of treatment de-
escalation rather than outright cessation and the effect of dis-
continuation in patients in MR3 who never achieved MR4 in
the phase 2 DESTINY trial. Patients were enrolled if they had
received the TKI for more than 3 years and were in stable
MR4 or in stable MR3 but not MR4 lasting for more than
12 months. Patients were treated with half standard dose: ima-
tinib 200 mg daily, dasatinib 50 mg daily, or nilotinib 200 mg
twice daily for 12 months. Relapse was considered as the loss
of MR3 on two consecutive samples and the primary endpoint
was to establish the proportion of patients who lost MR3 after
de-escalation strategy. One hundred and seventy-four patients
were enrolled, 49 in the MR3 cohort, and 125 in the MR4
cohort. During the de-escalation phase, 12 patients
experienced a recurrence of disease. Only 2% of patients re-
lapsed in the MR4 cohort compared to 19% in the MR3 co-
hort, regardless of the type of TKI. Loss of response was not
associated with age, gender, performance status, prior TKI or
duration of response [22]. The last follow-up at 24 months
showed a TFR of 78% for the MR4 cohort and of less than
40% for the MR3 cohort. The probability of TFR for the MR4
cohort was higher if compared to patients enrolled in the
EURO-SKI trial [23].
TFR Studies Involving Nilotinib
The ENESTFreedom study is the first prospective, phase 2,
single-arm study that evaluated the discontinuation of
nilotinib as first-line treatment. The trial enrolled CP patients
treated with frontline nilotinib for > 2 years and in sustained
MR4.5 for more than 1 year. Patients had to restart treatment
after the loss of MR3. Overall, 215 patients entered the con-
solidation phase and 190 were enrolled in the TFR phase. The
median duration of nilotinib prior to TFR was 43.5 months
and the median time from the first MR4.5 to TFR entry was
30.4 months. Median age at study entry was 55 years (range
21–86) and 28 patients were stratified as having a high Sokal
risk. At 96 weeks, the TFR was estimated to be 48.9%, be-
cause 93 of the 190 patients remained off treatment and in
MR3; 88 patients had a sustained MR4.5. Compared to the
last follow-up reported of 48 weeks, five patients were no
longer in TFR, three because they lost MR3 after 48 weeks,
and two because they discontinued the study without loss of
MR3.The estimated rate of treatment-free survival at 96weeks
was 50.9%. Of the 88 patients who reinitiated nilotinib due to
loss of MR3, 87 (98.9%) regained MR3 and 81 (92%)
regained MR4.5. A sub-analysis was conducted that showed
that the TFR rate at 48 weeks was different according to the
Sokal risk at baseline (62.9, 50, and 32.1% for low, interme-
diate, and high risk, respectively) and the BCR-ABL1 level in
the consolidation phase (52.9% for patients who persisted
with a transcript level < 0.0032% in all assessments and
40% for patients with a transcript level > 0.0032% in ≥ 1 as-
sessment). Overall, eight deaths were reported and two of
them were for cardiac reasons (one in consolidation phase
and one in reinitiation phase). Musculoskeletal pain was re-
ported as a side effect at discontinuation in 34% of patients in
the first 48 weeks and decreased to 9% in the subsequent
48 weeks, as also the incidence of other adverse events [24•].
Nilotinib was also tested as second-line treatment in the
ENESTop study that enrolled patients treated with imatinib
for more than 3 years with detectable molecular response
who switched to nilotinib for more than 2 years and
discontinued when a stable MR4.5 was reached. One hundred
and twenty-six patients entered the TFR phase, median age
was 56 years (range 21–86) and theywere treated for a median
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of 77.9 months with imatinib followed by nilotinib. The me-
dian exposure to nilotinib was 53 months. At 96 weeks from
the start of the TFR phase, 67 of the 126 patients (53.2%)
remained in TFR (relapse threshold considered as the loss of
MR4 or confirmed loss of MR3). Between 48 and 96 weeks,
73 patients were considered non-responders: of them, 4 for a
confirmed loss of MR4 and 2 patients who discontinued for a
pregnancy and for the patient’s decision. Of 56 patients who
reinitiated nilotinib, 52 (92.9%) regained MR4 and MR4.5 in
a median time of 12 and 13 months, respectively.
Musculoskeletal pain occurred in 47.9% of patients during
the first 48 weeks and in 15% of patients in the second period,
between 48 and 96 weeks. A total of 3 deaths occurred, none
due to disease [25].
TFR Studies Involving Dasatinib
The DASFREE is a phase 2 study that enrolled patients who
were on dasatinib for more than 2 years as first-line or subse-
quent therapy, with confirmed deep molecular response
(MR4.5) for more than 1 year prior to enrolment, and achieved
a 1-log reduction in BCR-ABL1 from baseline within 3–
6.5 months from the start of dasatinib. Relapse was considered
as the loss of MR3. An interim analysis was presented with 71
patients enrolled out of 79 planned. The first 30 patients were
presented and 11 patients lost MR3. EFS was 63% at 1 year.
Median time on dasatinib prior to discontinuation was
40 months for patients who lost MMR and 55 months for
patients who retained MMR. No transformation events or
deaths were observed. After discontinuation, five patients
had musculoskeletal adverse events [26].
The D-STOP trial is a prospective multicenter trial that
discontinued dasatinib used as consolidation for 2 years in
patients who had undetectable BCR-ABL1 levels after ima-
tinib. Molecular relapse was defined as two successive posi-
tive RQ-PCR tests within 1 month.
Sixty-five patients received consolidation therapy and 54
discontinued dasatinib treatment after maintenance of deep
molecular response for 2 years. The estimated overall TFS
was 62.9% (48.5–74.2) at 12 months. There was no signifi-
cant difference in estimated TFS between males and females
or Sokal’s score at diagnosis [27].
Second Discontinuation Attempt
The RE-STIM trial is a multicenter observational study that
enrolled 70 patients who re-attempted a second discontinua-
tion after the first failure. The loss ofMR3was the threshold to
consider a patient in relapse. After a median follow-up of
38 months, 45 patients lost the response and the majority of
relapses, as for the first discontinuation attempt, occurred
within the first 6 months. The TFR at 12 months was 48%
and at 36 months 35%. None of the patients progressed to a
blast phase and the same TKI received before discontinuation
was restarted in 27 relapsed patients (60%). At the last follow-
up, 34 patients regained MR4.5 within a median time of
6.5 months. The analysis of prognostic factors associated to
maintenance of molecular response after discontinuation
showed that in patients who remained in deep molecular re-
sponse within the first 3 months after the first discontinuation
the TFR was 72% after the second attempt, whereas it was
36% for the others [28•].
Table 2 Overview of second generation TKIs discontinuation trials
Study No. of
pts
Treatment Response required
at study entry
Relapse threshold Median duration
of therapy at study entry
TFR outcome
STOP 2G TKI 60 Nilotinib (30 pts)
or dasatinib
(30 pts) second line
>MR4.5 (undetectable
transcript for at
least 2 years)
Loss of MMR > 3 years after
resistance/
intolerance
to imatinib
63.3% at 1 year
DADI 63 Dasatinib second
line
BCR/ABL1 ratio
< 0.0069% for
at least 1 year
Loss of MR4 > 3 years 48% at 1 year
D-STOP 65 Dasatinib as
consolidation
for 2 years
MR4 for at least 2 years Loss of
confirmed MR4
> 3 years 62.9% at 1 year
DASFree 90 Dasatinib 1st or
2nd line
MR4.5 (undetectable
transcript for
at least 1 year)
Loss of MMR > 2 years 63% at 1 year
ENESTFreedom 190 Nilotinib
1st line
MR4.5 (undetectable
transcript for at
least 2 years)
Loss of MMR > 2 years 48.9% at 96 weeks
ENESTop 126 Nilotinib 2nd line MR4.5 (undetectable
transcript for at
least 2 years)
Loss of MR4 or
confirmed
loss of MR3
> 2 years 53.2% at 96 weeks
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The Japanese group reported on a second attempt of dis-
continuation in 10 patients treated with dasatinib who was
restarted after failure of the first discontinuation: the drug-
free survival was only 20% [29].
Prognostic Factors Associated to TFR
From all the studies discussed above, it emerged that the
Sokal stratification, the duration of imatinib treatment and,
for few studies, the previous exposure to interferon seem
the best predictive factors associated with a positive out-
come after discontinuation [9••, 11, 12•, 15, 17•]. The
French group analyzed the immunologic compartment in
51 patients enrolled in the STIM1 study (IMMUNOSTIM)
and found a low number of NK cells at the time of discon-
tinuation in patients who subsequently relapsed [30]. The
Nordic group analyzed the lymphocyte populations in 132
patients who were enrolled in the EURO-SKI study.
Immunophenotype was performed at the time of discontin-
uation and then at 1.6 and 12 months after relapse. The
results of the IMMUNOSTIM study were confirmed: pa-
tients who did not relapse after discontinuation showed an
increased number of NK cells with cytotoxic phenotype
(CD57+, CD56 dim) and an increased production of cyto-
kines (IFNγ, TNFα) both at the time of discontinuation
and at different subsequent time points. Molecular analysis
was performed in NK cells that were found to be EAT2
down-regulated. The authors suggested an adaptive nature
of these cells. No differences were detected between pa-
tients with or without previous exposure to IFN therapy. A
trend was reported towards an increase of the NK cell pop-
ulation in low Sokal risk patients [31•]. Another sub-
analysis of EURO-SKI was also conducted to study the
role of presenting antigen cells (pDC) that regulate lym-
phocyte T cell activation: 123 patients were investigated
for the expression of CD86, a ligand of CTLA-4, an inhib-
itor of lymphocyte T cell activation. A cut-off of CD86+
pDC/105 lymphocytes > 95 was found to be an indicator of
low relapse-free survival. Patients who relapsed had an
increased number of CD8+PD1+ T lymphocytes (T cell
exhaustion), without activity against residual disease
[32]. The impact of polymorphisms of ABCG2, OCT1
and ABCB1 were also studied: no differences were ob-
served in the expression of OCT1 and ABCB1 in relapsed
and non-relapsed patients. Indeed, a weak difference was
found in the expression of ABCG2 (1.1 vs 0.8%): patients
with a higher value of ABCG2 normalized per GUS had a
two-fold greater risk of relapse [33]. Finally, the UK group
reported an increased risk of relapse for patients carrying
an e13a2 type of transcript after discontinuation that needs
to be confirmed in a large series of patients [34].
General Recommendations
for Discontinuation
The last version of the 2013 European LeukemiaNet recom-
mendations suggested to continue indefinitely TKI therapy
and to appropriately discontinue only in a controlled clinical
trial [35••]. Hughes and Ross reported for the first time in
2016 how to move TFR into the clinical practice, suggesting
that patients who may be optimal discontinuation candidates
should be non-high Sokal risk at diagnosis, with a typical
transcript type, in CP with optimal past history of response
withmore than 8 years of treatment, inMR4.5 lasting for more
than 2 years. Patients who should be excluded from a discon-
tinuation proposal are patients with a prior advanced phase of
the disease, in failure, with less than 3 years of treatment, not
in MR4.5 and with a duration of deep molecular response of
less than 1 year [36••]. A position on discontinuation was also
taken by NCCN in the new version of the CML guidelines
2017: candidates to discontinuation are patients in chronic
phase, on therapy with one of the available TKIs for more
than 3 years, in stable MR4 for almost 2 years (documented
on at least four tests performed at least 3 months apart) and no
history of previous resistance. Monthly molecular monitoring
for the first 6 months has been suggested in a standardized
molecular laboratory with a limit of detection of MR4.5. The
guidelines also suggested consulting with a CML specialty
center to review the appropriateness for TKI discontinuation
and potential risks and benefits. The threshold to consider for
relapse is the loss of MR3 [37••]. Recently, ESMO guidelines
indicates that optimal candidates to discontinuation are non-
high Sokal risk patients, with typical quantifiable transcript, in
chronic phase, after optimal response to therapy, who have
reach MR4.5 with at least a stable MR4 for more than 2 years.
Institutional requirements for safe supervision of TFR include
availability of high quality internationally standardized, accu-
rate and sensitive RQ-PCR laboratory, with rapid turn-around
of test results (within 4 weeks) [38].
Patients’ Perspectives about Discontinuation
Few studies have reported on the perception of patients re-
garding treatment discontinuation. We collected the results
of a questionnaire administered to 1133 patients during re-
gional meetings in Italy. We asked “If in the future there is a
perfect and long-lasting response to the treatment, would you
accept the opportunity to interrupt the treatment for your
illness?”; 49% of patients answered that they would prefer
not to interrupt treatment being afraid of losing the results
achieved, while 16% of patients would like to discontinue
due to long-term intolerance and 20% did not have a firm
opinion [39]. A semi-structured interview to 40 CML patients
showed perceptions about treatment discontinuation and TFR,
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and on the potential impacts on QoL. Seventy-seven percent
of patients had received information about TFR and 58%were
cautiously positive about attempting discontinuation. The ma-
jority of patients interviewed would like to attempt discontin-
uation due to intolerance (75%) or for economic problems
(58%). Ninety percent of patients expressed concerns about
the possibility of developing resistance due to relapse or due to
a low perceived likelihood of successfully maintaining a TFR
[40]. Goldberg and colleagues also examined the perception
about TFR in 210 patients invited by mail to answer a 27-item
anonymous survey. The majority of them were on treatment
for more than 5 years, and 19% were treated with a second-
generation TKI. The survey specifically asked patients about
propensity for discontinuation: 42% of them were willing to
try, 34% wished to continue the TKI and 25% were uncertain.
Most of the patients wanting to discontinue did so because of
side effects (40%), economic problems (30%) and diminished
inconveniences (26%). Most patients refusing discontinuation
were worried about disease recurrence (58%) [41]. Finally, 87
patients answered a survey including CML-specific factors
such as disease history treatment toxicity and adherence.
The percentage of patients willing to discontinue increased
to 81%; reluctance to attempt this strategy was associated with
the need of additional information or a better understanding of
the available data [42].
Conclusions
All the studies published so far clearly demonstrate that dis-
continuation is feasible and safe if performed in patients with a
long-lasting deep molecular response, without reports of dis-
ease progression or clonal evolution. This possibility is chang-
ing profoundly physicians’ behavior towards patients and
TFR is always more frequently considered as a part of the
routine clinical practice. The correct selection of the optimal
candidates to discontinuation still remains a matter of debate
and there is urgent need of general recommendations on how
to identify patients and how to monitor them during the first
months of discontinuation. Preliminary data on the use of
second-generation TKIs does not seem to improve the results,
but does appear to impact on the median time from treatment
start to the stopping attempt. Patients’ perceptions change over
time and a better knowledge of the available data and specific
communications will improve the attitude to participate to this
strategy.
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